Search
PEG-uricase
go.drugbank.com/drugs/DB05321InvestigationalPEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment … of severe, treatment-refractory gout in the United States in 2006.
Categories: Compounds used in a research, industrial, or household settingCHF 4227
go.drugbank.com/drugs/DB05882ExperimentalThe compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingDiminazene
go.drugbank.com/drugs/DB03608ExperimentalThis substance is a solid. This compound belongs to the phenylhydrazines. … These are compounds containing a phenylhydrazide moiety, which consists of a hydrazide substituent attached to a phenyl group.
Synonyms: 4,4'-(1-triazene-1,3-diyl)bis-benzenecarboximidamideVSF-173
go.drugbank.com/drugs/DB05753InvestigationalIt is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness. … VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect.
Aplaviroc
go.drugbank.com/drugs/DB06497InvestigationalA spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.
Categories: Heterocyclic Compounds, 1-RingBGB-DXP593
go.drugbank.com/drugs/DB16357Investigational[L27401] It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants … With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)) by BeiGene.
AZD2389
go.drugbank.com/drugs/DB22104InvestigationalNCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants). … AZD2389 is an investigational small molecule inhibitor of fibroblast activation protein (FAP).[L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g.
Nicotinamide adenine dinucleotide phosphate
go.drugbank.com/drugs/DB03461ExperimentalA coenzyme composed of ribosylnicotinamide 5'-phosphate (NMN) coupled by pyrophosphate linkage to the 5'-phosphate adenosine 2',5'-bisphosphate. … It serves as an electron carrier in a number of reactions, being alternately oxidized (NADP+) and reduced (NADPH). (Dorland, 27th ed)
Categories: Heterocyclic Compounds, 2-RingCardarine
go.drugbank.com/drugs/DB05416InvestigationalCardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. … Cardarine has been investigated for the treatment of Obesity, Lipid Disorders, and Cardiovascular Disease.
Categories: Heterocyclic Compounds, 1-RingPilaralisib
go.drugbank.com/drugs/DB11772InvestigationalPilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). … Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.
Categories: Heterocyclic Compounds, 2-Ring, Phosphatidylinositol 3-Kinases, antagonists & inhibitors